NCT03617523 - Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations | Biotech Hunter

Enrollment

240

Participants

Timeline

Start Date

September 10, 2018

Primary Completion Date

November 12, 2018

Study Completion Date

November 12, 2018

Conditions

Influenza

Interventions

BIOLOGICAL

Fluzone Quadrivalent vaccine, 2018-2019 formulation

Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

BIOLOGICAL

Flublok Quadrivalent vaccine, 2018-2019 formulation

Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

BIOLOGICAL

Fluzone High-Dose vaccine, 2018-2019 formulation

Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Trial Locations (3)

Investigational Site Number 8400003, Bardstown

Investigational Site Number 8400001, Metairie

Investigational Site Number 8400002, Salt Lake City

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY